FDA Grants Priority to J&J Schizophrenia Drug

The FDA has granted priority review to Johnson & Johnson’s new drug application for its schizophrenia treatment, which the company says is the longest dosing interval available.

from WSJ.com: US Business http://ift.tt/1Frp4p7
via IFTTT